To test this hypothesis, we performed a detailed histologic review of bladder tumors collected from 29 patients with locally advanced or metastatic bladder cancer that were treated with the anti-PD-L1 antibody atezolizumab on a therapeutic protocol (clinicaltrials.gov NCT02108652)6. Here, CD274 is linked to urinary bladder neoplasm.